DRIO (DarioHealth) FFO


DRIO DarioHealth Corp DRIO
62 GF Score
Price $6.06
GF Value $7.16
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is DarioHealth FFO?

FFO (Funds from operations) only applies to REITs.

DRIO
62GF Score
DarioHealth Corp DRIO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is DarioHealth (DRIO) Overvalued in 2026?

Based on GuruFocus' analysis, DarioHealth stock appears to be undervalued. The current stock price of $6.06 is trading 15.4% below its estimated GF Value™ of $7.16. GuruFocus considers DarioHealth to be Modestly Undervalued.

Key valuation signals for DRIO:

  • FFO:
  • GF Value™: $7.16 vs. price of $6.06 (15.4% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the DRIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DarioHealth Business Description

Address 322 West 57th Street, New York, NY, USA, 10019
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
62GF Score

Get the complete analysis for DRIO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.06
Price
$7.16
GF Value